Navigation Links
Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress

SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) highlighted today that its proprietary PEGylation technology is used in the novel therapeutic, Hematide(TM), a synthetic, peptide-based erythropoiesis-stimulating agent that is under development by Takeda Global Research & Development Center, Inc. and Affymax. Data were presented for Hematide(TM) today at the 45th ERA-EDTA Congress in Stockholm, Sweden, which showed that Hematide(TM) administered once every four weeks was well-tolerated and maintained mean hemoglobin levels between 11 and 12 g/dL in patients with CKD, both pre-dialysis and hemodialysis, over a 12-month period.(1)

"The data on Hematide(TM) demonstrate how Nektar's advanced PEGylation chemistry can be used in peptide mimetics to enable a once-monthly dosing schedule while maintaining efficacy," said Tim Riley, Vice President of PEGylation Research at Nektar. "This represents another example of the unique value and broad applicability of Nektar's PEGylation technology and its ability to enable new therapeutics that otherwise might not be possible."

Under the terms of an exclusive agreement between Nektar and Affymax, Nektar is entitled to receive royalties on the global sales of Hematide(TM) for all indications, as well as manufacturing revenues.

With the use of Nektar's advanced PEGylation technology, the properties of therapeutic agents, such as Hematide(TM), can be enhanced by increasing drug circulation time in the bloodstream, decreasing immunogenicity, and reducing dosing frequency. Nektar proprietary technology uses advanced conjugation chemistry and techniques to attach polyethylene glycol polymers to therapeutic agents.

About Hematide(TM)

Hematide(TM), a novel, synthetic, peptide-based erythropoiesis-stimulating agent (ESA), is a product candidate that has demonstrated the ability to stimulate the production of red blood cells. If proven safe and effective in clinical trials, it may offer physicians and patients an alternative therapy to recombinant erythropoietin, a hormone that stimulates red blood cell formation.

Affymax and Takeda are collaborating on the development of Hematide(TM). The product will be commercialized in the European Union by Takeda. Affymax is conducting Phase 3 clinical trials for Hematide(TM) to treat anemia in chronic renal failure indications. Takeda is also focusing on a recently initiated Phase 1 clinical trial to evaluate Hematide(TM) to treat chemotherapy-induced anemia in prostate, breast and non-small cell lung cancer patients. Hematide(TM) is a trademark of Affymax.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of Hematide(TM), the potential of Nektar's PEGylation Technology, and the overall prospects for Nektar's business. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) because Hematide(TM) is still in clinical development, the risk of failure is high and can occur at any stage due to many factors including but not limited to safety and efficacy considerations; (ii) Takeda and Affymax may fail to obtain regulatory approval for Hematide(TM) in one or more indications; (iii) if Hematide(TM) does receive regulatory approval, Nektar's actual manufacturing revenues and royalties from Hematide(TM) will depend on the level of sales by Takeda and Affymax; (iv) Nektar's efforts to develop product candidates based on its PEGylation Technology is subject to numerous scientific, clinical and regulatory risks and the risk of failure is high and can occur at any stage of development; and (v) Nektar's patent applications may fail to issue; patents that have issued may not be enforceable; or unanticipated intellectual property licenses from third parties may be required in the future. Other important risks and uncertainties are detailed in the Nektar's filings with the Securities and Exchange Commission including its most recent Quarterly Report on Form 10-Q filed on May 9, 2008. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward- looking statements, whether as a result of new information, future events, or otherwise.


Tim Warner (650) 283-4915 or

Stephan Herrera (415) 488-7699 or

Jennifer Ruddock (650) 631-4954 or


(1) MacDougall I. et al, Interim evaluation of long-term safety and

tolerability of Hematide during maintenance treatment of anaemia in

patients with chronic kidney disease, presented on 12 May 2008 at the

45th ERA-EDTA congress, Stockholm, Sweden. SOURCE: Affymax press


SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Selected to Join the NASDAQ Biotechnology Index
2. USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical
3. QLT reports initial proof of concept data for punctal plug delivery technology
4. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon
7. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
8. Guided Surgery Technology Gaining Popularity in the Dental Implant Market
9. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
10. eResearchTechnology Reports First Quarter 2008 Results
11. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
Post Your Comments:
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):